Clinical Trials Logo

ALK-activated Tumors clinical trials

View clinical trials related to ALK-activated Tumors.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01742286 Completed - Clinical trials for ALK-activated Tumors

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Start date: August 28, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose pharmacokinetics when administered orally to pediatric patients with ALK-activated tumors, with and without food.